Why European Biotechnology Companies Need a Global Commercial Strategy Before Their Next Funding Round

By Ron Lanton III, Esq. | President, Lanton Strategies International B.V.

European biotechnology companies preparing for their next funding round should be able to explain more than their clinical development plans. Investors also need to understand where a product will be sold, how it will be reimbursed, what it will cost to bring to market and whether the company has the resources to commercialize it independently.

These questions can influence how much capital a company needs, how its business is valued and what commercial rights it may eventually need to license to a partner.

Europe's Financing and Commercialization Challenge

Europe has a strong scientific research base, yet biotechnology companies continue to face difficulties securing the capital necessary to advance clinical development and expand their operations.

The European Commission's proposed European Biotech Act acknowledges these financing and commercialization challenges. While public funding and policy reforms may help address some of these obstacles, biotechnology executives still need to make decisions about how their companies will generate revenue.

For some companies, the answer may involve entering the United States. Others may pursue regional licensing agreements, international commercial partnerships or a combination of these approaches.

Each decision carries different financial implications that should be understood before approaching investors.

Reimbursement Should Influence Commercial Planning

As discussed in our previous article on clinical evidence and reimbursement, regulatory approval does not guarantee reimbursement or patient access.

In Europe, the EU Health Technology Assessment Regulation introduces joint clinical assessments for certain medicines, including new oncology treatments and advanced therapy medicinal products. Pricing and reimbursement decisions, however, remain the responsibility of individual member states.

In the United States, biotechnology companies must consider Medicare, Medicaid, commercial insurers, pharmacy benefit managers and the distribution arrangements applicable to their products.

Clinical evidence that supports regulatory approval may not answer every question raised by payers. Differences in clinical comparators, treatment costs, patient populations and expected outcomes can affect reimbursement discussions.

Companies that understand these requirements during clinical development can better estimate their commercial expenses, expected revenue and additional evidence requirements.

International Licensing and Commercial Partnerships

A biotechnology company does not necessarily need to establish its own commercial operations in every market.

Licensing arrangements and commercialization partnerships can provide access to capital, established distribution networks and regional market expertise. However, executives need to understand the economic value of the commercial rights they are negotiating.

Granting worldwide rights to a partner may provide immediate financing while limiting future revenue opportunities. Retaining rights in selected markets may offer greater long-term value but require additional investment.

Companies should evaluate these alternatives before financial pressures reduce their negotiating flexibility.

Technology Infrastructure and Cross-Border Risk

Artificial intelligence, cloud computing and international research collaborations are becoming important components of biotechnology development.

Companies relying on external technology providers should understand where their research data is stored, who can access it, how intellectual property is protected and whether their technology arrangements create exposure to international trade restrictions or data protection requirements.

These considerations can affect operating costs, research continuity, commercial partnerships and investor due diligence.

Technology infrastructure deserves a place in the company's commercial and financial planning.

Preparing for the US Market During Clinical Development

European biotechnology companies considering US market entry should begin evaluating the opportunity well before regulatory approval.

Understanding the potential US patient population, competitive landscape, reimbursement options, distribution requirements and commercial infrastructure can help executives determine whether direct commercialization is financially realistic or whether a partnership would provide greater value.

These decisions also help establish a more credible funding requirement.

A company raising capital to complete clinical development may need a substantially different financing plan from one preparing to establish US commercial operations.

How Lanton Strategies International Can Help

Based in Amsterdam, Lanton Strategies International B.V. works with biotechnology, pharmaceutical and healthcare companies evaluating commercial opportunities across the United States, European Union and United Kingdom.

We assist companies with pricing and reimbursement strategy, market access, international trade policy, commercial expansion and the policy considerations that can affect financing and business development decisions.

For biotechnology executives preparing their next funding round, understanding the commercial potential of a product can be just as important as demonstrating its scientific potential.

For European biotechnology companies preparing to enter the United States, Lanton, Lanton & Sosa Law PLLC, with offices in Boston and Washington, D.C., provides US legal counsel on regulatory compliance, commercial agreements, corporate transactions, employment law and outside general counsel services.

Previous
Previous

From Capital to Commercialization: Q4 2026 Healthcare Investor Briefing

Next
Next

What European Biotech Companies Should Know Before Entering the U.S. Market